{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intranasal+ketamine", "query": { "intervention": "intranasal ketamine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intranasal+ketamine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T00:18:14.123Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02682225", "title": "Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Abuse" ], "interventions": [ { "name": "Intravenous placebo", "type": "DRUG" }, { "name": "Intranasal placebo", "type": "DRUG" }, { "name": "Intravenous racemic ketamine", "type": "DRUG" }, { "name": "Esketamine 112 mg", "type": "DRUG" }, { "name": "Esketamine 84 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 55, "start_date": "2016-03-25", "completion_date": "2017-01-09", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02682225" }, { "nct_id": "NCT02418585", "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Treatment-resistant Depression" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 236, "start_date": "2015-08-07", "completion_date": "2017-11-06", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Orange, California • San Rafael, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Rafael", "state": "California" }, { "city": "Maitland", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02418585" }, { "nct_id": "NCT01304147", "title": "Intranasal Ketamine in Treatment-Resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James Murrough", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2011-10", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-02-08", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01304147" }, { "nct_id": "NCT04480918", "title": "University of Iowa Interventional Psychiatry Service Patient Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Treatment Resistant Depression", "Major Depressive Episode", "Major Depression", "Major Depressive Disorder", "Bipolar Disorder", "Bipolar Depression", "Obsessive-Compulsive Disorder" ], "interventions": [ { "name": "Electroconvulsive Therapy (ECT)", "type": "DEVICE" }, { "name": "Transcranial Magnetic Stimulation (TMS)", "type": "DEVICE" }, { "name": "Ketamine", "type": "DRUG" }, { "name": "Esketamine", "type": "DRUG" }, { "name": "Deep Transcranial Magnetic Stimulation (dTMS)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Mark Niciu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1000, "start_date": "2020-11-02", "completion_date": "2050-08", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04480918" }, { "nct_id": "NCT02866071", "title": "Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Traumatic Pain" ], "interventions": [ { "name": "Ketamine Hydrochloride", "type": "DRUG" }, { "name": "Placebo-Comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jason McMullan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 224, "start_date": "2017-10-03", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2022-12-16", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02866071" }, { "nct_id": "NCT02417064", "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Treatment-resistant Depression" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 346, "start_date": "2015-08-10", "completion_date": "2018-02-20", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02417064" }, { "nct_id": "NCT01170247", "title": "Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation in Pediatric Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sedation" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 3, "start_date": "2011-01", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01170247" }, { "nct_id": "NCT03067974", "title": "Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Failed Moderate Sedation During Procedure", "Ketamine Adverse Reaction" ], "interventions": [ { "name": "Ketamine Hcl 100Mg/Ml Inj", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "7 Years", "sex": "ALL", "summary": "2 Years to 7 Years" }, "enrollment_count": 10, "start_date": "2017-09-21", "completion_date": "2019-01-22", "has_results": false, "last_update_posted_date": "2019-01-28", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03067974" }, { "nct_id": "NCT03039192", "title": "54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 226, "start_date": "2017-06-09", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Garden Grove", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03039192" }, { "nct_id": "NCT00662883", "title": "Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PMI-150 (intranasal ketamine HCl); mometasone furoate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Javelin Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 18, "start_date": "2007-11", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2008-04-22", "last_synced_at": "2026-09-20T00:18:14.123Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00662883" } ] }